Form 4 for LLY Lilly (Eli)
Accepted 2022-02-17 00:00:00 ET · period of report 2022-02-16 · accession 0000059478-22-000065 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-17 | 2022-02-16 | LLY | Van Naarden Jacob | SVP, CEO LoxoONC, Pres LlyONC | F - Tax | $243.84 | -2,186 | 7,967 | -22% | -$533.0K |
| D | 2022-02-17 | 2022-02-16 | LLY | Van Naarden Jacob | SVP, CEO LoxoONC, Pres LlyONC | M - OptEx | $0.00 | +5,461 | 10.2K | +116% | $0 |
| D | 2022-02-17 | 2022-02-16 | LLY | Van Naarden Jacob | SVP, CEO LoxoONC, Pres LlyONC | M - OptEx | $0.00 | -5,461 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-16 | F | D | 2,186 | $243.84 | 7,967 | D | — | — | |
| 2 | Common | Common Stock | 2022-02-16 | M | A | 5,461 | $0.00 | 10,153 | D | — | — | |
| 3 | Derivative | Restricted Stock Unit | 2022-02-16 | M | D | 5,461 | $0.00 | 0 | D | — · 2022-02-16 to 2022-02-16 | 5,461 Common Stock | (F2) Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. |